1. Home
  2. UTHR vs SNX Comparison

UTHR vs SNX Comparison

Compare UTHR & SNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • SNX
  • Stock Information
  • Founded
  • UTHR 1996
  • SNX 1980
  • Country
  • UTHR United States
  • SNX United States
  • Employees
  • UTHR N/A
  • SNX N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • SNX Retail: Computer Software & Peripheral Equipment
  • Sector
  • UTHR Health Care
  • SNX Technology
  • Exchange
  • UTHR Nasdaq
  • SNX Nasdaq
  • Market Cap
  • UTHR 13.8B
  • SNX 11.7B
  • IPO Year
  • UTHR 1999
  • SNX 2003
  • Fundamental
  • Price
  • UTHR $312.23
  • SNX $149.88
  • Analyst Decision
  • UTHR Buy
  • SNX Strong Buy
  • Analyst Count
  • UTHR 13
  • SNX 10
  • Target Price
  • UTHR $382.00
  • SNX $149.80
  • AVG Volume (30 Days)
  • UTHR 762.5K
  • SNX 536.4K
  • Earning Date
  • UTHR 07-30-2025
  • SNX 09-25-2025
  • Dividend Yield
  • UTHR N/A
  • SNX 1.22%
  • EPS Growth
  • UTHR 17.94
  • SNX 19.95
  • EPS
  • UTHR 25.63
  • SNX 8.55
  • Revenue
  • UTHR $3,077,800,000.00
  • SNX $60,007,297,000.00
  • Revenue This Year
  • UTHR $14.37
  • SNX $4.71
  • Revenue Next Year
  • UTHR $6.59
  • SNX $4.14
  • P/E Ratio
  • UTHR $12.18
  • SNX $17.51
  • Revenue Growth
  • UTHR 17.62
  • SNX 6.60
  • 52 Week Low
  • UTHR $266.98
  • SNX $92.23
  • 52 Week High
  • UTHR $417.82
  • SNX $153.70
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 58.33
  • SNX 59.90
  • Support Level
  • UTHR $303.59
  • SNX $143.09
  • Resistance Level
  • UTHR $317.31
  • SNX $153.70
  • Average True Range (ATR)
  • UTHR 7.91
  • SNX 3.11
  • MACD
  • UTHR 0.90
  • SNX -0.41
  • Stochastic Oscillator
  • UTHR 80.53
  • SNX 73.57

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About SNX TD SYNNEX Corporation

TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.

Share on Social Networks: